Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S J Russell

Showing results (131-140 of 145) with videos related to

Pageof 15
Sort By:
Leukemia|October 26, 2013
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsS K Kumar, A Dispenzieri, M Q Lacy, et al.
Blood Cancer Journal|June 17, 2017
Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myelomaP Ravi, S Kumar, W Gonsalves, et al.
Kidney International|April 4, 2008
Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chainsN Leung, M A Gertz, S R Zeldenrust, et al.
Blood Cancer Journal|July 30, 2016
Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myelomaP Ravi, S Kumar, J T Larsen, et al.
Blood Cancer Journal|March 21, 2015
Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myelomaW I Gonsalves, N Leung, S V Rajkumar, et al.
Leukemia|January 19, 2007
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapyA K Stewart, P L Bergsagel, P R Greipp, et al.
Blood Cancer Journal|March 12, 2016
Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Leukemia|December 17, 2015
Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatmentT V Kourelis, F K Buadi, M A Gertz, et al.
Blood Cancer Journal|September 2, 2017
Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Leukemia|September 10, 2010
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)M Q Lacy, S R Hayman, M A Gertz, et al.
Pageof 15

Showing results (131-140 of 145) with videos related to

Sort By:
Pageof 15
Leukemia|October 26, 2013
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patientsS K Kumar, A Dispenzieri, M Q Lacy, et al.
Blood Cancer Journal|June 17, 2017
Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myelomaP Ravi, S Kumar, W Gonsalves, et al.
Kidney International|April 4, 2008
Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chainsN Leung, M A Gertz, S R Zeldenrust, et al.
Blood Cancer Journal|July 30, 2016
Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myelomaP Ravi, S Kumar, J T Larsen, et al.
Blood Cancer Journal|March 21, 2015
Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myelomaW I Gonsalves, N Leung, S V Rajkumar, et al.
Leukemia|January 19, 2007
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapyA K Stewart, P L Bergsagel, P R Greipp, et al.
Blood Cancer Journal|March 12, 2016
Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Leukemia|December 17, 2015
Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatmentT V Kourelis, F K Buadi, M A Gertz, et al.
Blood Cancer Journal|September 2, 2017
Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myelomaM Binder, S V Rajkumar, R P Ketterling, et al.
Leukemia|September 10, 2010
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)M Q Lacy, S R Hayman, M A Gertz, et al.
Pageof 15